Rosenberg JE - Search Results

1

Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Apolo AB, et al. Among authors: rosenberg je. J Natl Cancer Inst. 2013 Apr 3;105(7):499-503. doi: 10.1093/jnci/djt015. Epub 2013 Feb 14. J Natl Cancer Inst. 2013. PMID: 23411591 Free PMC article.

2

Prostate cancer update.

Rosenberg J, Small EJ. Rosenberg J, et al. Curr Opin Oncol. 2003 May;15(3):217-21. doi: 10.1097/00001622-200305000-00007. Curr Opin Oncol. 2003. PMID: 12778015 Review.

3

Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

Rosenberg JE, Small EJ. Rosenberg JE, et al. Clin Prostate Cancer. 2004 Sep;3(2):122-4. doi: 10.3816/cgc.2004.n.022. Clin Prostate Cancer. 2004. PMID: 15479496 Review.

4

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.

Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. Rosenberg JE, et al. Cancer. 2005 May 15;103(10):2035-41. doi: 10.1002/cncr.21023. Cancer. 2005. PMID: 15812833 Free article. Clinical Trial.

5

Update on chemotherapy for advanced bladder cancer.

Rosenberg JE, Carroll PR, Small EJ. Rosenberg JE, et al. J Urol. 2005 Jul;174(1):14-20. doi: 10.1097/01.ju.0000162039.38023.5f. J Urol. 2005. PMID: 15947569 Review.

6

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

7

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. Among authors: rosenberg je. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

8

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.

Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. Garcia JA, et al. Among authors: rosenberg je. BJU Int. 2007 Mar;99(3):519-24. doi: 10.1111/j.1464-410X.2007.06659.x. BJU Int. 2007. PMID: 17407512

9

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Rosenberg JE, et al. Cancer. 2007 Aug 1;110(3):556-63. doi: 10.1002/cncr.22811. Cancer. 2007. PMID: 17577218 Free article. Clinical Trial.

10

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. Lin AM, et al. Among authors: rosenberg je. Clin Genitourin Cancer. 2007 Jun;5(5):323-8. doi: 10.3816/CGC.2007.n.011. Clin Genitourin Cancer. 2007. PMID: 17645829 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters